Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers

Quarterly Journal of Nuclear Medicine

Volumn 46, Issue 2, 2002, Pages 113-121

  Suarez M ^a   Perez Castejon M J ^a   Jimenez A ^a   Domper, M ^a   Ruiz, G ^a   Montz, R ^a   Carreras, J L ^a  

^a Instituto Tecnologico PET   (Spain)

Author keywords

Breast neoplasms, radionuclide imaging; Tomography, emission computed; Tumor markers, biological

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; HORMONE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE CANCER; BREAST CANCER; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS; PERICARDIUM; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; THYROID CANCER; WHOLE BODY SCANNER; X RAY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FALSE POSITIVE REACTIONS; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036621020     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Sensitivity of serum tumor markers CEA and CA 15.3 in breast cancer recurrence and correlation with different prognostic factors
2. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer
3. Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for a tumoral activity. Results in 1219 patients
4. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors
5. Determination of the specificities of monoclonal antibodies recognizing members of the CEA family using a panel of transfectants
6. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
7. 2000 update of recommendations for the use of tumor markers in breast colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
8. The applications of PET in clinical oncology
9. Intratumoral distribution of tritiated-FDG in breast carcinoma: Correlation between Glut-1 expression and FDG uptake
10. Accuracy of whole-body Fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
11. 18F-Fluorodeoxiglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma
12. 131I whole body scans and elevated serum thyroglobulin levels
13. Utility of fluorine 18-Fluorodeoxiglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels
14. Comparison of TAC, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
15. PET: The merming of biology and imaging into molecular imaging
16. Positron emission tomography with fluorine-18-deoxiglucose in the detection and staging of breast cancer
17. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience
18. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer
19. 18F-Fluorodeoxiglucose in management of recurrencent colorectal cancer